172 related articles for article (PubMed ID: 1733803)
1. Chromatographic quantitation of plasma and erythrocyte pentosidine in diabetic and uremic subjects.
Odetti P; Fogarty J; Sell DR; Monnier VM
Diabetes; 1992 Feb; 41(2):153-9. PubMed ID: 1733803
[TBL] [Abstract][Full Text] [Related]
2. Accumulation of carbonyls accelerates the formation of pentosidine, an advanced glycation end product: carbonyl stress in uremia.
Miyata T; Ueda Y; Yamada Y; Izuhara Y; Wada T; Jadoul M; Saito A; Kurokawa K; van Ypersele de Strihou C
J Am Soc Nephrol; 1998 Dec; 9(12):2349-56. PubMed ID: 9848790
[TBL] [Abstract][Full Text] [Related]
3. ELISA of pentosidine, an advanced glycation end product, in biological specimens.
Taneda S; Monnier VM
Clin Chem; 1994 Sep; 40(9):1766-73. PubMed ID: 8070089
[TBL] [Abstract][Full Text] [Related]
4. Pentosidine: a molecular marker for the cumulative damage to proteins in diabetes, aging, and uremia.
Sell DR; Nagaraj RH; Grandhee SK; Odetti P; Lapolla A; Fogarty J; Monnier VM
Diabetes Metab Rev; 1991 Dec; 7(4):239-51. PubMed ID: 1813279
[TBL] [Abstract][Full Text] [Related]
5. Quantification of the cross-link pentosidine in serum from normal and uremic subjects.
Takahashi M; Kushida K; Kawana K; Ishihara C; Denda M; Inoue T; Horiuchi K
Clin Chem; 1993 Oct; 39(10):2162-5. PubMed ID: 8403403
[TBL] [Abstract][Full Text] [Related]
6. Increased pentosidine, an advanced glycation end product, in plasma and synovial fluid from patients with rheumatoid arthritis and its relation with inflammatory markers.
Miyata T; Ishiguro N; Yasuda Y; Ito T; Nangaku M; Iwata H; Kurokawa K
Biochem Biophys Res Commun; 1998 Mar; 244(1):45-9. PubMed ID: 9514872
[TBL] [Abstract][Full Text] [Related]
7. Plasma advanced glycosylation end-products in maintenance haemodialysis patients.
Odetti P; Cosso L; Pronzato MA; Dapino D; Gurreri G
Nephrol Dial Transplant; 1995 Nov; 10(11):2110-3. PubMed ID: 8643178
[TBL] [Abstract][Full Text] [Related]
8. Implication of altered redox regulation by antioxidant enzymes in the increased plasma pentosidine, an advanced glycation end product, in uremia.
Ueda Y; Miyata T; Hashimoto T; Yamada H; Izuhara Y; Sakai H; Kurokawa K
Biochem Biophys Res Commun; 1998 Apr; 245(3):785-90. PubMed ID: 9588192
[TBL] [Abstract][Full Text] [Related]
9. Autoxidation products of both carbohydrates and lipids are increased in uremic plasma: is there oxidative stress in uremia?
Miyata T; Fu MX; Kurokawa K; van Ypersele de Strihou C; Thorpe SR; Baynes JW
Kidney Int; 1998 Oct; 54(4):1290-5. PubMed ID: 9767546
[TBL] [Abstract][Full Text] [Related]
10. Analytical strategy for the assessment of the protein glycation status in uremic patients by high-performance liquid chromatography.
Floridi A; Trizza V; Paolotti P; Lucarelli C
J Chromatogr A; 1999 Jun; 846(1-2):65-71. PubMed ID: 10420599
[TBL] [Abstract][Full Text] [Related]
11. Plasma pentosidine levels in uremic patients before and after hemodialysis.
Takahashi M; Kushida K; Ishihara C; Denda M; Inoue T
Scand J Urol Nephrol; 1995 Jun; 29(2):131-4. PubMed ID: 7569788
[TBL] [Abstract][Full Text] [Related]
12. Creatine plays a direct role as a protein modifier in the formation of a novel advanced glycation end product.
Miyazaki K; Nagai R; Horiuchi S
J Biochem; 2002 Oct; 132(4):543-50. PubMed ID: 12359068
[TBL] [Abstract][Full Text] [Related]
13. Accumulation of albumin-linked and free-form pentosidine in the circulation of uremic patients with end-stage renal failure: renal implications in the pathophysiology of pentosidine.
Miyata T; Ueda Y; Shinzato T; Iida Y; Tanaka S; Kurokawa K; van Ypersele de Strihou C; Maeda K
J Am Soc Nephrol; 1996 Aug; 7(8):1198-206. PubMed ID: 8866413
[TBL] [Abstract][Full Text] [Related]
14. Levels of pentosidine in the vitreous of eyes with proliferative diabetic retinopathy, proliferative vitreoretinopathy and retinal detachment.
Tomé CC; De Rojas Silva MV; Rodríguez-García J; Rodríguez-Segade S; Sánchez-Salorio M
Graefes Arch Clin Exp Ophthalmol; 2005 Dec; 243(12):1272-6. PubMed ID: 15947940
[TBL] [Abstract][Full Text] [Related]
15. Maillard reaction-mediated molecular damage to extracellular matrix and other tissue proteins in diabetes, aging, and uremia.
Monnier VM; Sell DR; Nagaraj RH; Miyata S; Grandhee S; Odetti P; Ibrahim SA
Diabetes; 1992 Oct; 41 Suppl 2():36-41. PubMed ID: 1526333
[TBL] [Abstract][Full Text] [Related]
16. Direct quantification of pentosidine in urine and serum by HPLC with column switching.
Takahashi M; Hoshino H; Kushida K; Kawana K; Inoue T
Clin Chem; 1996 Sep; 42(9):1439-44. PubMed ID: 8787701
[TBL] [Abstract][Full Text] [Related]
17. The advanced glycation endproduct pentosidine and monocyte activation in uremia.
Friedlander MA; Witko-Sarsat V; Nguyen AT; Wu YC; Labrunte M; Verger C; Jungers P; Descamps-Latscha B
Clin Nephrol; 1996 Jun; 45(6):379-82. PubMed ID: 8793229
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms for the formation of glycoxidation products in end-stage renal disease.
Weiss MF; Erhard P; Kader-Attia FA; Wu YC; Deoreo PB; Araki A; Glomb MA; Monnier VM
Kidney Int; 2000 Jun; 57(6):2571-85. PubMed ID: 10844627
[TBL] [Abstract][Full Text] [Related]
19. Influence of hemodialysis membrane type on pentosidine plasma level, a marker of "carbonyl stress".
Jadoul M; Ueda Y; Yasuda Y; Saito A; Robert A; Ishida N; Kurokawa K; Van Ypersele De Strihou C; Miyata T
Kidney Int; 1999 Jun; 55(6):2487-92. PubMed ID: 10354298
[TBL] [Abstract][Full Text] [Related]
20. Measurement of pentosidine in human plasma protein by a single-column high-performance liquid chromatography method with fluorescence detection.
Scheijen JL; van de Waarenburg MP; Stehouwer CD; Schalkwijk CG
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Mar; 877(7):610-4. PubMed ID: 19188098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
